To include your compound in the COVID-19 Resource Center, submit it here.

Zogenix reports additional Phase III data for ZX008 in Dravet syndrome

Zogenix Inc. (NASDAQ:ZGNX) reported additional data from the Phase III Study 1 to treat Dravet syndrome showing that once-daily 0.8 mg/kg ZX008 as adjunctive therapy led to a “much improved”

Read the full 304 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE